Vulvovaginal Candidiasis Treatment Market Status and Prospects 2023 to 2033Posted by Ganesh Shinde on January 18th, 2023  The global vulvovaginal candidiasis treatment market is currently valued at US$ 1035 million in 2023, with a CAGR of 4.5% expected. Because of technological advancements in the healthcare sector, the market is expected to reach US07 million by 2033. According to FMI, a market research and competitive intelligence provider, the vulvovaginal candidiasis industry grew at a 4.3% CAGR between 2018 and 2022. Vaginal yeast infection is a common fungal infection and is called candidal vaginitis or candidal vulvovaginitis Symptoms of vaginal yeast infection include itching, burning sensation or pain during urination or sexual intercourse, swelling, rashes, and redness. Candida albicans is the most common cause of human fungal infections. The most common cause of fungal urinary tract infections is Candida species (UTIs). Candida UTIs can occur in the lower urinary tract or, in some cases, ascend to the kidneys. In many cases, the antifungal drug fluconazole can be used. Individuals' VVC prevalence has increased due to an increase in diabetes cases and repeated antibiotic use. Vulvovaginal Candidiasis Treatment Market: Segmentation Valuable information covered in the FMI’s Vulvovaginal Candidiasis Treatment market report has been segregated into key segments and sub-segments. Vulvovaginal Candidiasis Treatment Market by Drug Class:
Vulvovaginal Candidiasis Treatment Market by Route of Administration:
Vulvovaginal Candidiasis Treatment Market by Distribution Channel:
View More Details@ https://www.futuremarketinsights.com/reports/vulvovaginal-candidiasis-treatment-market Key players covered in the report include:
Like it? Share it! More by this author |